Ptc Therapeutics (PTCT) Total Current Liabilities (2012 - 2026)

Ptc Therapeutics' Total Current Liabilities history runs 15 years deep, the most recent figure standing at $923.6 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 55.13% year-over-year to $923.6 million in Q1 2026; TTM through Mar 2026 was $923.6 million, a 55.13% increase from a year earlier, with the FY2025 full-year figure at $968.4 million, up 66.69% from the prior year.
• Total Current Liabilities declined to $923.6 million in Q1 2026 per PTCT's latest filing, from $968.4 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $968.4 million in Q4 2025 and bottomed at $406.2 million in Q4 2022.
• The 5-year median for Total Current Liabilities is $581.0 million (2024), against an average of $602.4 million.
• Biggest YoY gain for Total Current Liabilities was 95.0% in 2022; the steepest drop was 20.24% in 2022.
• Year by year, Total Current Liabilities stood at $406.2 million in 2022, then surged by 48.46% to $603.1 million in 2023, then fell by 3.67% to $581.0 million in 2024, then jumped by 66.69% to $968.4 million in 2025, then slipped by 4.63% to $923.6 million in 2026.
• Per Business Quant, the three latest PTCT Total Current Liabilities figures stand at $923.6 million (Q1 2026), $968.4 million (Q4 2025), and $866.2 million (Q3 2025).